Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American…

Overview of attention for article published in Journal of Clinical Oncology, May 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

news: 9 news outlets
blogs: 1 blog
twitter: 23 X users

patent: 1 patent
googleplus: 1 Google+ user
guideline: 2 clinical guideline sources

Readers on

mendeley: 114 Mendeley

So far, Altmetric has seen 31 X posts from 23 X users, with an upper bound of 112,512 followers.

lenalidomide added to azacitidine improved ORR and duration for 70 year olds with CMML; better if fewer mutations https://t.co/Vvz73NYY6a

RT @HayderSaeed_MD: Azacitidine+Lenalidomide in Higher-Risk CMML do better than Aza only! SWOG S1117 @jco_asco #mdssm #mpdsm https://t.co/j…

New2Trip: Randomized Phase II Study of Azacitidine Alone or in Combination w/ Lenalidomide or w/ Vorinostat in … https://t.co/4aYA53pOIC

Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk MDS and CMML: SWOG S1117 https://t.co/PFmrHSItZw

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 27 additional X posts.